-
Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)
(PAR-20-316)
National Institute of Neurological Disorders and Stroke
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute on Drug Abuse
National Institute of Environmental Health Sciences
National Eye Institute
Application Receipt Date(s): September 14, 2021, September 13, 2022, September 12, 2023
-
NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
(PAR-21-092)
National Institute on Drug Abuse
Application Receipt Date(s): July 26, 2021; July 25, 2022; July 25, 2023
-
Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional)
(PAR-21-099)
National Institute of Neurological Disorders and Stroke
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Cancer Institute
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Eye Institute
National Institute of Mental Health
National Institute of Nursing Research
National Center for Complementary and Integrative Health
National Institute of Biomedical Imaging and Bioengineering
Office of Behavioral and Social Sciences Research
Application Receipt Date(s): February 16, 2021, February 16, 2022, February 16, 2023
-
Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional)
(PAR-21-100)
National Institute of Neurological Disorders and Stroke
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Cancer Institute
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Eye Institute
National Institute of Mental Health
National Institute of Nursing Research
National Center for Complementary and Integrative Health
Office of Behavioral and Social Sciences Research
National Institute on Minority Health and Health Disparities
Application Receipt Date(s): February 5, 2021, February 5, 2022, February 5, 2023
-
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
(PAR-21-101)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): June 9, 2021, February 17, 2022, October 13, 2022, June 8, 2023 and February 15, 2024
-
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
(PAR-21-102)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): Standard dates apply.
The first standard due date for this FOA is February 5, 2021
-
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
(PAR-21-103)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): Standard dates apply.
The first standard due date for this FOA is February 5, 2021
-
Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional)
(RFA-DA-21-015)
National Institute on Drug Abuse
Application Receipt Date(s): February 26, 2021
-
Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)
(RFA-DA-21-016)
National Institute on Drug Abuse
Application Receipt Date(s): February 26, 2021
-
Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
(RFA-DA-21-031)
National Institute on Drug Abuse
Application Receipt Date(s): January 26, 2021
-
Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
(RFA-DA-21-032)
National Institute on Drug Abuse
Application Receipt Date(s): January 26, 2021